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Objective: The aim of this study was to determine whether the Z-scores for bone
mineral density measured in childhood and early adolescence and adjusted for
chronological age, stature, and bone age, are able to predict adult bone status in
patients with cystic ﬁbrosis.
Material and Methods: This study was retrospective. The medical records of
20 patients with cystic ﬁbrosis were examined. All patients had had several bone
density test, with at least one since age 18. The adult bone mineral density (BMD)
Z-scores were compared with those measured during the ﬁrst densitometry in
childhood and another from prepuberty.
Results: Differences between the chronological age, stature, and bone age were
noted at the ﬁrst and the prepubertal densitometries. When discordance was noted
between BMD adjusted for chronological age and BMD adjusted for bone age or
stature, the adjustment for chronological age was signiﬁcantly more predictive of
the results seen in adulthood (p< 0.01).
Conclusion: This study shows in a small number of patients that the childhood
BMD Z-score adjusted for chronological age best predicts adult bone status.
Adjustment for stature or bone age may overestimate bone mineralization, thereby
delaying the implementation of appropriate therapy.
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Background: Reduced body mass density (BMD) has been reported in earlier
studies of cystic ﬁbrosis (CF) patients. Quantitative ultrasonography (QUS) method
recently has been introduced for the assessment of BMD. This technique is safe,
noninvasive, easy to use, and radiation-free, making it ideal for use in children.
QUS offers information on skeletal status, matrix microstructure and is important
when assessing fracture risk.
Aim: In this our study the frequency of bone and mineral disorders in patients with
CF using QUS method was assessed.
Material and methods: The study group included 33 patients with CF (18 males)
aged 2.5−21 years. The diagnosis of CF had been made using a clinical features,
sweat chloride test and identiﬁcation of CFTR mutation. CF patients were assessed
by QUS at the Sunlight Omnisense 7000S bone sonometer (Israel), witch measures
the speed of sound (SOS) propagating axially along the distal 1/3 radius. Z-score
was used for bone status evaluation, as standard deviation (DS) from the mean BMD
of an age and gender matched control population (Z-score >−1 DS, osteopenia −
Z-score <−1 DS and >−2.5 DS, osteoporosis − Z-score <−2.5 DS).
Results: All examined CF patients were divided on two groups according to age of
everyone (I group 17 children aged 2.5−12 years, II group 15 children 12 years).
Z-score in all children were signiﬁcantly lower (−2.86±0.3 DS) than age normal
values. Children under 12 years, had the mean of Z-score −2.52±0.3 DS. In children
older than 12 years, Z-score were −3.22±0.5 DS. The values of Z-score were normal
in 3 children.
Conclusion: The monitoring of BMD in patients with CF is an important tool for
detection of bone complications (osteopenia, osteoporosis) and fractures prevention
with an adequate treatment.
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Bone loss is highly prevalent in our CF population (70%) and is associated with
risk factors;age, low vit D levels, low BMI and CFRDM [1]. The evidence that
low BMD is a predictor of fracture risk is inconclusive and whilst there is some
data to suggest that bisphosphonates increase BMD [2], the signiﬁcance of bone
loss in our centre is unclear. We hypothesised that bone loss occurs in patients with
known risk factors and treatment using CF Trust Bone Mineralisation Guidelines
results in improved BMD. However, we present 4 case studies which show that
not all patients “ﬁt this picture” and that treatment may not result in improved
BMD. Of 140 DEXA scans over 6 years we present several individual patients
whose results conﬂict with received wisdom and challenge the new guidelines.
Case 1: 37 yr old male: high risk for bone loss(Fev1 17%, BMI 20.4, CFRDM, low
VIT D*. Treated with Alendronate for 5 yrs. DEXA scan currently lower than at
initial presentation. Case 2: Female aged 43, high risk for bone loss (Fev1 25%, BMI
17 CFRDM, low VIT D) but DEXA scan normal. Case 3: 39 yr old male, CFRDM,
VIT D 82. BMI 21.9, Fev1 31% DEXA scan improved despite no treatment and
worsening health. Case 4: 48 yr old Male, PS, very healthy (BMI 31.5, FEV1
100% but low Vit D and DEXA −2.8 T score). Deterioration in scan at 2.5 yrs post
Alendronate despite stable health. Based on available evidence, we have adopted the
guidelines for detection and management of bone loss. However, given the diversity
of presentation and differing results after treatment as illustrated, we conclude that
detection and management of bone loss continues to be challenging.
*Vitamin D (25-OH nmols/L range;25–170)
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Normal growth and nutritional status are associated with better pulmonary function
in CF patients. Recently a nutritional score (NS) was proposed for identiﬁcation
of patients at risk of malnutrition (McDonald CM, JPGN 2008), that is based on
weight gain, height velocity and BMI percentile.
We have compared this NS with other nutritional indices (Height and BMI
percentiles) and investigated the association of nutritional risk classiﬁcation by each
index with pulmonary function. We evaluated 302 patients in the age range between
2−20 years. The agreement in the nutritional categories ranking (high, moderate or
low risk) of BMI percentile, height percentile and the NS was analyzed. The relative
risk (RR) of having a FEV1< 80% was determined in the group of patients deﬁned
at risk of malnutrition by each parameter.
The NS identiﬁed a higher proportion of patients with or at risk of malnutrition than
height and BMI percentiles (31.5% vs 26.5% and 15.2% respectively) and showed
a moderate agreement with the BMI percentile classiﬁcation of risk (k = 0.491,
p< 0.001). The RR of having a FEV1< 80% was increased in patients with BMI
percentile <25th (2.2 CI 1.4−3.7) and also <50th (2.3 CI 1.5−3.9). Patients with
height percentile <25th and patients identiﬁed at risk by the NS did not show a
signiﬁcant RR of having a FEV1< 80%.
The examined parameters used for nutritional screening differ in nutritional risk
classiﬁcation. The NS and height percentile did not show a signiﬁcant association
with FEV1. In patients with BMI percentile <25th an increased RR of pulmonary
deterioration was detected, that remains elevated in those not achieving the CFF
nutritional goal (BMI percentile >50th).
